Shared Neurobiology of Fragile X Syndrome and Autism (R01)

The summary for the Shared Neurobiology of Fragile X Syndrome and Autism (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Shared Neurobiology of Fragile X Syndrome and Autism (R01)
	CFDA Number:	93.24293.853
	CFDA Description:	Mental Health Research Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Income Security and Social Services Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-07-284
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jan 09, 2007
	Creation Date:	Sep 03, 2008
	Original Closing Date for Applications:	Sep 07, 2008 Multiple Receipt Dates - See Link to Full Announcement for details.
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Feb 07, 2009
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	93.865 -- Child Health and Human Development Extramural Research

Applicants Eligible for this Grant: Independent school districts Small businesses Private institutions of higher education For profit organizations other than small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education County governments City or township governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Grant Description: Purpose. The National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD) have entered into a public-private partnership with the Canadian Institutes of Health Research (CIHR), the Health Research Board, Ireland (HRB), Cure Autism Now (CAN), the National Alliance for Autism Research (NAAR), Autism Speaks and the FRAXA Research Foundation (FRAXA) to jointly sponsor this Funding Opportunity Announcement (FOA), which is aimed at characterizing, understanding and treating etiological and pathophysiological mechanisms common to both Fragile X syndrome (FXS) and autism (including autism spectrum disorders such as Rett syndrome). Between 2.5% and 6% of individuals with autistic feature have FXS, and approximately 15% to 25% of children with FXS have autism. An additional 50% to 90% of children with FXS exhibit some symptoms and features associated with autism, including poor eye contact, hand flapping, hand biting, speech perseveration and other language abnormalities and problems, as well as tactile defensiveness, mental retardation in the moderate to severe range, developmental delay, sensory hyperarousal, and social anxiety with mood liability. Researchers have argued that autism and autistic symptoms in FXS reflect a common etiological or pathophysiological pathway underlying the two conditions. Ongoing basic neuroscience research on FXS in model systems like the mouse and fly are providing a wealth of information at multiple levels subcellular, cellular, and intercellular networks or circuits to delineate the neurobiology of this disorder. These studies should dissect components of the neurobiology of autism, especially in patients with both FXS and autism, and identify novel targets for new drugs to treat both disorders. Applications submitted in response to this FOA should focus on a topic related to understanding neural pathways, circuits, systems and molecules that play a role in the etiology or pathophysiology of FXS and may be implicated in autism (including autism spectrum disorders such as Rett syndrome). Studies emphasizing the identification of drug targets for new therapeutic drugs to treat FXS and autism are particularly encouraged. Research projects supported under this FOA that include human subjects should include children affected with both FXS and autism and animal studies may include several models systems, e.g., mouse, fly and zebrafish. Basic neuroscience research in model systems should focus on both FXS and autism. Research more exclusively focused on autism that would not be covered under this FOA may be submitted under PA-06-390, PA-06-391, or PA-06-392.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-07-284.html http://grants.nih.gov/grants/guide/pa-files/PA-07-284.html
Grant Announcement Contact: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster